The Full Wiki

More info on Benserazide

Benserazide: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 14919-77-8
ATC code  ?
PubChem 2327
ChemSpider 2237
Chemical data
Formula C 10H15N3O5  
Mol. mass 257.243 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion Renal and fecal
Therapeutic considerations
Pregnancy cat. B3(AU)
Legal status POM (UK) (with levodopa)
Routes  ?
 Yes check.svgY(what is this?)  (verify)

Benserazide (also called Serazide or Ro 4-4602) is a peripherally-acting aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor,[1] which is unable to cross the blood-brain barrier.


It is used in the management of Parkinson's disease in combination with L-DOPA (levodopa) as co-beneldopa (BAN), under the brand names Madopar in the UK and Prolopa in Canada, both made by Roche. Benserazide is not approved for use in the US; carbidopa is used instead for the same purpose. These combinations are also used for the treatment of restless legs syndrome[2].


Levodopa is a precursor to the neurotransmitter dopamine which is administered to increase its levels in the central nervous system. However, most levodopa is decarboxylated to dopamine before it reaches the brain, and since dopamine is unable to cross the blood-brain barrier, this translates to little therapeutic gain with strong peripheral side effects.

Benserazide inhibits this decarboxylation, and since it itself cannot cross the blood-brain barrier, this allows dopamine to build up solely in the brain instead. Adverse effects caused by peripheral dopamine, such as nausea and arrhythmia, are minimized. However, benserazide cannot reduce the centrally-mediated side effects of levodopa, particularly dyskinesia.

Benserazide has little therapeutic effect on its own, and is only administered in combination with levodopa.


  1. ^ Shen H, Kannari K, Yamato H, Arai A, Matsunaga M (March 2003). "Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats". The Tohoku journal of experimental medicine 199 (3): 149–59. PMID 12703659.  
  2. ^ Ryan, Melody; Slevin, John T. (2006). "Restless legs syndrome". American Journal of Health-System Pharmacy. 63 (17): 1599-1612. Retrieved on 2008-02-06.

Got something to say? Make a comment.
Your name
Your email address